Therapeutic potential of thalidomide and its analogues in the treatment of cancer

Anticancer Research

Volumn 35, Issue 11, 2015, Pages 5767-5772

  Sherbet, Gajanan V ^a,b  

^a INSTITUTE FOR MOLECULAR MEDICINE   (United States)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Angiogenesis; Immunotherapy; Invasion; Metastasis; Review; Signalling systems; Thalidomide analogues

Indexed keywords

BORTEZOMIB; DNA VACCINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IPILIMUMAB; LENALIDOMIDE; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MONOCLONAL ANTIBODY; PHOSPHATIDYLINOSITOL 3 KINASE; POMALIDOMIDE; PROTEIN KINASE B; TEMSIROLIMUS; THALIDOMIDE; THALIDOMIDE DERIVATIVE; VASCULOTROPIN; ANGIOGENESIS INHIBITOR;

ANGIOGENESIS; APOPTOSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CARCINOGENESIS; CELL MOTILITY; CELL PROLIFERATION; CLINICAL EVALUATION; CLINICAL TRIAL (TOPIC); COLORECTAL CARCINOMA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; KIDNEY METASTASIS; MULTIPLE MYELOMA; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SIGNAL TRANSDUCTION; TERATOGENESIS; TUMOR GROWTH; TUMOR MODEL; ANALOGS AND DERIVATIVES; ANIMAL; FEMALE; NEOPLASMS; PATHOLOGY; PREGNANCY;

ANGIOGENESIS INHIBITORS; ANIMALS; FEMALE; HUMANS; NEOPLASMS; PREGNANCY; THALIDOMIDE;

EID: 84946073292     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Ito T, Ando H, Suzuki T, Ogura T, Hotta K, Imamura Y, Yamaguchi Y and Handa H: Identification of a primary target of thalidomide teratogenicity. Science 327: 1345-1350, 2010.
2. Botting J: The history of thalidomide. Drug News Perspect 15: 604-611, 2002.
3. Bartlett JB, Keith Dredge K and Dalgleish AG: The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 4: 314-322, 2004.
4. Sherbet GV: Molecular approach to targeted therapy for multiple sclerosis (in press), 2015.
5. D'Amato RJ, Loughnan MS, Flynn E and Folkman J: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91: 4082-4085, 1994.
6. Kenyon BM, Browne F and D'Amato RJ: Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res 64: 971-978, 1997.
7. Lu L, Payvandi F, Wu L, Zhang LH, Hariri RJ, Man HW, Chen RS, Muller GW, Hughes CC, Stirling DI, Schafer PH and Bartlett JB: The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions. Microvasc Res 77: 78-86, 2009.
8. Medinger M, Halter J, Heim D, Buser A, Gerull S, Stern M and Passweg J: Angiogenic markers in plasma cell myeloma patients treated with novel agents. Anticancer Res 35: 1085-1090, 2015.
9. Ling YG, Liebes L, Ng B, Buckley M, Elliott PJ, Adams J, Jiang JD, Muggia FM and Perez-Soier R: S-341, a Novel Proteasome Inhibitor, Induces Bcl-2 Phosphorylation and Cleavage in Association with G2-M Phase Arrest and Apoptosis. Mol Cancer Ther 1: 841-849, 2002.
10. Liu WM, Henry JY, Meyer, B, Bartlett JB, Dalgleish AG and Galustian C: Inhibition of metastatic potential in colorectal carcinoma in vivo and in vitro using immunomodulatory drugs (IMiDs). Br J Cancer 101: 803-812, 2009.
11. Liu WM, Laux H, Henry JY, Bolton TB, Dalgleish AG and Galustian C. A microarray study of altered gene expression in colorectal cancer cells after treatment with immunomodulatory drugs: differences in action in vivo and in vitro. Mol Biol Rep 37: 1801-1814, 2010.
12. Sherbet GV: Growth factors and their receptors in cell differentiation, cancer and cancer therapy, 2011, Elsevier. London and Waltham MA, USA.
13. Keifer JA, Guttridge DC, Ashburner BP and Baldwin AS Jr.: Inhibition of NF-?B activity by thalidomide through suppression of IkappaB kinase activity. J Biol Chem 276: 22382-22387, 2001.
14. Liu WM , Strauss SJ , Chaplin T , Shahin S , Propper DJ, Young BD, Joel SP and Malpas JS: s-Thalidomide has a greater effect on apoptosis than angiogenesis in a multiple myeloma cell line. Hematol J 5: 247-254, 2004.
15. Yee AJ, Hari P, Marcheselli R, Mahindra AK, Cirstea DD, Scullen TA, Burke JN, Rodig SJ, Hideshima T, Laubach JP, Ghobrial IM, Schlossman RL, Munshi NC, Anderson KC, Weller EA, Richardsom PG and Raje NS: Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide. Br J Heamatol 166: 401-409, 2014.
16. Ganesan P, Piha-Paul S, Naing A, Falchook G, Wheler J, Janku F, Zinner R, Laday S, Kies M and Tsimberidou AM: Phase I clinical trial of lenalidomide in combination with temsirolimus in patients with advanced cancer. Invest New Drugs 31: 1505-1513, 2013.
17. Fecteau JF, Corral LG, Ghia EM, Gaidarova S, Futalan D, Bharati IS, Cathers B, Schwaederle M, Cui B, Lopez-Girona A, Messmer D and Kipps TJ: Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21(WAF1/CIP1)-dependent mechanism independent of functional p53. Blood 124: 1637-1644, 2014.
18. Andersen KC. Lenalidomide and thalidomide: mechanisms of action-similarities and differences. Semin Hematol 42: S3-8, 2005).
19. Sherbet GV. Therapeutic strategies in cancer biology and pathology, Elsevier, London and Wlatham MA, USA 2013, ISBN: 978-0-12-416570-0.
20. Kim R, Emi M, Tanabe K and Arihiro K. Immunosuppressive networks during malignant progression. Cancer Res 66: 5527-5536, 2006.
21. Kim R, Emi M and Tanabe K. Cancer immunosuppression and autoimmune disease: beyond immunosuppressive networks for tumour immunity. Immunology 119: 254-264, 2006.
22. Yang L and Carbone DP. Tumor host immune interactions and dendritic cell dysfunction. Adv Cancer Res 82: 13-27, 2004.
23. Pardoll DM: The blockade of immune checkpoints in cancer immunotherapy Nature Rev Cancer 12: 252-264, 2012
24. Kim JW and Elder JP. Prospects for targeting PD-1 and PD-L1 in various tumor types. Oncology New York 28: 15-28, 2014.
25. Gorgun G, Samur MK, Cowens KB, Paula S, Bianchi G, Anderson JE, White RE, Singh A, Ohgushi H, Suzuki R, Kikuchi S, Harada T, Hideshima T, Tai YT, Laubach JP, Raje NS, Magrangeas F, Minvielle S, Avet-Loiseau H, Munshi NC, Dorfman D, Richardson PG and Anderson KC: Lenalidomide enhances immune checkpoint blockade induced immune response in multiple myeloma. Clin Cancer Res 2015.
26. Rei M, Pennington DJ and Silva-Santos B: The emerging protumor role of gamma delta T lymphocytes: Implications for cancer immunotherapy. Cancer Res 75: 798-802, 2015.
27. De Keersmaecker, B Fostier, K, Corthals, J, Wilgenhof, S, Heirman, C, Aerts, JL Thielemans K and Schots R: Immunomodulatory drugs improve the immune environment for dendritic cell-based immunotherapy in multiple myeloma patients after autologous stem cell transplantation. Cancer Immunol Immunother 63: 1023-1036, 2014.
28. Busch A, Zeh D, Janzen V, Mugge LO, Wolf D, Fingerhut L, Hahn-Ast C, Maurer O, Brossart P and von Lilienfeld-Toal M: Treatment with lenalidomide induces immunoactivating and counter-regulatory immunosuppressive changes in myeloma patients. Clin Expt Immunol 177: 439-453, 2014.
29. Huseby ES, Huseby PG, Shah S, Smith R and Stadinski BD: Pathogenic CD8 T Cells in multiple sclerosis and its experimental models. Front Immunol 3, art no. 64, 2012.
30. Xiang R, Luo Y, Niethammer AG and Reisfeld RA: Oral DNA vaccines target the tumor vasculature and microenvironment and suppress tumor growth and metastasis. Immunol Rev 222: 117-128, 2008.
31. Jellbauer S, Panthel K, Hetrodt JH and Rüssmann H: CD8 T-Cell Induction against Vascular Endothelial Growth Factor Receptor 2 by Salmonella for Vaccination Purposes against a Murine Melanoma. PLoS ONE 7(4): e34214, 2012.
32. D'Amato RJ, Hernandez-McClain J, Saxena S and Khan M: Lenalidomide therapy for metastatic renal cell carcinoma. Am J Clin Oncol Cancer Clin Trials 31: 244-249, 2008.
33. Patel PH, Kondagunta GV, Schwartz L, Ishill N, Bacik J, DeLuca J, Russo P and Motzer RJ: Phase II trial of lenalidomide in patients with metastatic renal cell carcinoma. Invest New Drugs 26: 273-276, 2008.
34. Vestermark LW, Larsen S, Lindelov B and Bastholt L: A phase II study of thalidomide in patients with brain metastases from malignant melanoma. Acta Oncol 47: 1526-1530, 2008.
35. Wienkers LC and Padbury GE: Stereochemical elements associated with drug metabolism and toxicity. Part VII. Role of Metabolism in Toxicology and Pharmacology. Encyclopaedia Drug Interactions, Wiley On Line Library, DOI: 10.1002/9780470921920.edm081, 2012.
36. Lee CJJ, Shibata N, Wiley MJ and Wells PG: Fluorothalidomide: A characterization of maternal and developmental toxicity in rabbits and mice. Toxicol Sci 122: 157-169, 2011.
37. Man HW, Corral LG, Stirling DI and Muller GW: Alpha-fluorosubstituted thalidomide analogues. Bioorg Medicinal Chem Lett 13: 3415-3417, 2003.